CHINA HEALTH GRP HD-10 Total Liabilities
CHINA HEALTH GRP HD-10 total liabilities. Based on the latest financial reports, CHINA HEALTH GRP HD-10 (VNL1) has total liabilities worth €31.60 Million EUR (≈ $36.95 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VNL1 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CHINA HEALTH GRP HD-10 (2021–2024)
Total liabilities of CHINA HEALTH GRP HD-10 from 2021 to 2024. This chart illustrates how CHINA HEALTH GRP HD-10's total liabilities have evolved over time, based on quarterly financial data.
CHINA HEALTH GRP HD-10 Competitors by Total Liabilities
The table below lists competitors of CHINA HEALTH GRP HD-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Volvere PLC
LSE:VLE
|
UK | GBX11.95 Million |
|
Powell Max Limited Class A Ordinary Shares
NASDAQ:PMAX
|
USA | $17.46 Million |
|
PT Century Textile Industry Tbk
JK:CNTX
|
Indonesia | Rp911.16 Billion |
|
Tupperware Brands Corporation
NYSE:TUPBQ
|
USA | $1.20 Billion |
|
Ortel Communications Limited
NSE:ORTEL
|
India | Rs4.43 Billion |
|
Integragen
PA:ALINT
|
France | €3.26 Million |
|
Aloro Mining Corp
V:AORO
|
Canada | CA$2.44 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down CHINA HEALTH GRP HD-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CHINA HEALTH GRP HD-10 assets under control.
Liquidity & Leverage Metrics
CHINA HEALTH GRP HD-10 Total Liabilities Ratios Explained
CHINA HEALTH GRP HD-10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CHINA HEALTH GRP HD-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CHINA HEALTH GRP HD-10 (2021–2024)
The table below shows the annual total liabilities of CHINA HEALTH GRP HD-10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €31.24 Million ≈ $36.53 Million |
-11.16% |
| 2023-12-31 | €35.17 Million ≈ $41.11 Million |
-4.29% |
| 2022-12-31 | €36.74 Million ≈ $42.96 Million |
-5.19% |
| 2021-12-31 | €38.75 Million ≈ $45.31 Million |
-- |
About CHINA HEALTH GRP HD-10
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research… Read more